Cardiomyopathy with lethal arrhythmias associated with inactivation of KLHL24


1 Department of Pathology and Genetics, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
2 Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.
3 Molecular and Clinical Sciences Institute, St George’s University of London, Cranmer Terrace, London, UK.
4 Department of Neurology, Linköping University Hospital, Linköping, Sweden.
5 Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran.
6 Pediatric Pathology Research Center, Research Institute for Children Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
7 Department of Medical and Health Sciences, Linkoping University, Linkoping Sweden.
8 Department of Pathology, Karolinska University Hospital, Stockholm, Sweden.
9 Institute of Human Genetics, Julius Maximilians University Würzburg, Würzburg, Germany.
10 Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
11 Bioinformatics Core Facilities, Sahlgrenska Academy, University of Gothenburg, Sweden
12 Next Generation Genetic Polyclinic, Mashhad, Iran.
13 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
14 Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.
15 Innovative Medical Research Center, Faculty of Medicine, Mashhad Branch, Islamic Azad University, Mashhad, Iran.

*Correspondence: Anders Oldfors; Sahlgrenska University Hospital, Dept of Pathology and Genetics, Gula stråket 8, 413 45 Gothenburg, Sweden, phone number +46 31 342 2084, anders.oldfors@gu.se (A.O.). Yalda Jamshidi; Genetics Centre, Molecular and Clinical Sciences Institute, St George’s University London, Cranmer Terrace, London SW17 0RE, United Kingdom, phone number +44 207 7250509, yjamshid@sgul.ac.uk (Y.J.).
†These authors contributed equally to this work.
Abstract

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder, yet the genetic cause of up to 50% of cases remains unknown. Here we show that mutations in KLHL24 cause hypertrophic cardiomyopathy in humans. Using genome-wide linkage analysis and exome sequencing we identified homozygous mutations in KLHL24 in two consanguineous families with HCM. Of the eleven young affected adults identified, three died suddenly and one had a cardiac transplant due to heart failure. KLHL24 is a member of the kelch-like protein family, which act as substrate-specific adaptors Cullin E3 ubiquitin ligases. Endomyocardial and skeletal muscle biopsies from affected individuals of both families demonstrated characteristic alterations, including accumulation of desmin intermediate filaments. Knock-down of the zebrafish homologue khl24a results in heart defects similar to that described for other HCM-linked genes providing additional support for KLHL24 as a HCM-associated gene. Our findings reveal a crucial role for KLHL24 in cardiac development and function.
Introduction

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder, and the prevalence is approximately 1 in 500 individuals (1). In most cases, HCM is caused by autosomal dominant mutations in genes encoding proteins of the sarcomere; among these, the most common genes are slow/beta cardiac myosin heavy chain (MYH7) and the cardiac myosin-binding protein C (MYBPC3) located within the thick filament, and the thin filament-associated troponin T (TNNT2) and troponin I (TNNI3). Pathogenic variants of genes associated with metabolic disorders may also cause a cardiomyopathy that mimics HCM, but usually with recessive inheritance. HCM is diagnosed on cardiac imaging, showing unexplained hypertrophy together with typical electrocardiographic abnormalities (1). Next-generation sequencing panels for clinical genetic testing for HCM provide a definitive molecular diagnosis in up to 50% of patients (2). Still, many patients remain without a clear genetic diagnosis, suggesting that additional causes of HCM remain to be identified (1).

Here, we report a novel cardiomyopathy that mimics HCM with recessive inheritance identified in two unrelated families. Several individuals died of sudden cardiac arrest in young adulthood. Endomyocardial and skeletal muscle biopsy demonstrated characteristic alterations and we provide evidence that the disease is caused by inactivation of the Kelch-like protein 24 by molecular genetic investigations and functional studies in zebrafish.

Results

A novel autosomal recessive cardiomyopathy causing lethal arrhythmias and heart failure

We describe two families with autosomal recessive cardiomyopathy originating from Iraq (family A) and Iran (family B) (Fig. 1). In summary affected members of both families presented with symptoms characteristic of hypertrophic cardiomyopathy including recurrent
syncope, dyspnea on exertion and palpitations (Table 1). No signs of muscular atrophy or weakness were found, and nerve conduction studies were normal. Importantly, the clinical phenotype is associated with a poor prognosis due to lethal arrhythmias and cardiac failure.

Diagnostic histopathological hallmarks in cardiac and skeletal muscle tissue

Individual III:2 in family A had a cardiac transplant at the age of 26. The heart explant showed, similar to a previous endomyocardial biopsy, hypertrophy and scattered cardiomyocytes with polyglucosan. There was also interstitial fibrosis and small macrophage infiltrates that were occasionally associated with polyglucosan bodies (Fig. 2A-G).

A myocardial biopsy of individual III:1 from family A was performed at 30 years of age and revealed myocyte hypertrophy and occasional polyglucosan bodies. Electron microscopy showed accumulation of glycogen, tubular structures, and irregularly arranged intermediate filaments in the intermyofibrillar regions (Fig. 2H-I).

Skeletal muscle biopsy in individual III:1 and III:2 in family A and V:5 in family B demonstrated characteristic focal subsarcolemmal and intermyofibrillar accumulation of glycogen. The accumulated material also stained with antibodies against desmin. This accumulation resulted in a jagged appearance at the edges of the majority of both type 1 and type 2 muscle fibres giving them a characteristic cogwheel-like appearance (Fig. 3A-H and Supplementary Fig. 1). The accumulated material also stained for NADH-tetrazolium reductase (NADH-TR) but was negative for the mitochondria-specific enzyme succinate dehydrogenase (SDH), indicating presence of tubules derived from the sarcoplasmic reticulum (Supplementary Fig. 2). Electron microscopy confirmed that the accumulated material consisted of intermediate filaments, measuring 8-12 nm in diameter, glycogen and tubular structures (Fig. 3I-J and Supplementary Fig. 1 and 2).
Mutations in \textit{KLHL24} are associated with a novel cardiomyopathy

Two affected individuals from each family were investigated by exome sequencing (ES).

In family A, a homozygous nonsense mutation in the Kelch-like family member 24 gene (\textit{KLHL24}) (NM_017644.3) (Fig. 4A-D) was identified in both siblings (III:1 and III:2). The variant at position c.1048G>T p.Glu350* (Fig. 4B) lies in exon 4 of the \textit{KLHL24} gene which encodes the functional kelch domains of the protein, and is located in an extended 8.7Mb region of homozygosity. The parents were heterozygous carriers of the mutation.

In family B, linkage mapping of the five affected individuals revealed one large (with a homozygosity interval greater than 1 Mb) region of homozygosity on chromosome 3 with an estimated LOD score of 3.6 assuming an autosomal recessive mode of inheritance (Supplementary Fig. 3A). The ~3.4 Mb homozygous region on chromosome 3 (hg19, chr3:182,207,825-185,614,988) is defined by rs9877496 to rs73175592 (Fig. 4E, Supplementary Table 3 and Supplementary Fig. 1A-B). Copy number variant (CNV) analysis of genome-wide SNP-array genotyping data did not highlight any potentially pathogenic shared CNVs in the affected individuals. ES data from individuals V:2 and V:4 identified only one homozygous likely disease-causing variant in this region. The missense mutation at position c.917G>A in the \textit{KLHL24} gene, changes the amino acid arginine to histidine at position 306 (Fig. 4C). The Arg306 residue is highly conserved among species (Fig. 4D) as well as among different Kelch-like proteins (Supplementary Fig. 4A). Sanger sequencing confirmed the variants and genetic screening demonstrated the same homozygous mutation in the two additional affected individuals in Family B (V:5, V:7). The parents of the homozygous affected individuals in Family B were heterozygous carriers of the mutation (IV:5, IV:6). The affected offspring of an additional branch of Family B (IV:9) was also
found to be homozygous for the p.Arg306His mutation, and the parents (IV:10 and IV:11) heterozygous confirming the AR pattern of inheritance.

Neither of the identified KLHL24 variants were represented in the Greater Middle Eastern Variome (GME) including populations from Iran and Iraq. The p.Arg306His mutation was also not found in 500 ethnically matched in-house exomes.

In the Genotype-Tissue Expression (GTEx) Portal Database (http://www.gtexportal.org) KLHL24 shows the highest expression in skeletal muscle, followed by lung and the left ventricle of the heart (Fig. 4F), supporting a role for this protein in muscle (3).

Desmin is upregulated in KLHL24 associated cardiomyopathy

Dominant translation initiation codon mutations in KLHL24 were recently demonstrated to be associated with a type of epidermolysis bullosa in two independent studies (4, 5). Both studies indicated that intermediate filament proteins might be substrates for the E3 ubiquitin ligase KLHL24. However no substrate for KLHL24 has yet been identified in skeletal and heart muscle, despite its expression in these tissues. Based on the finding of accumulation of intermediate filaments in the heart and skeletal muscle and accumulation of desmin as revealed by immunohistochemistry we performed western blot analysis of desmin, which was markedly up regulated (Fig. 5).

Inactivation of klhl24a in zebrafish results in cardiac failure

To assess the function of KLHL24 in heart development, we used zebrafish as a vertebrate model system. Zebrafish have two KLHL24 homologues, Klhl24a and Klhl24b with 78% and 85% identity to the human protein respectively (Supplementary Fig. 6). We determined the spatiotemporal mRNA expression of klhl24a and klhl24b with whole-mount in situ hybridization. The klhl24a mRNA was detected at early time points and was by 22 hours post
fertilization (hpf) expressed in the cardiac cone, especially in the central region harbouring ventricular myocytes (Fig. 6A). At 72 hpf, when the heart is an S-shaped loop, *klhl24a* transcripts were detected in the ventricle and at a lower level in the atrium (Fig. 6C).

Contrary, *klhl24b* expression was not detected in the developing heart although observed in other tissues (Fig. 6B-D). The heart specific localisation of *klhl24a* therefore led us to focus on the involvement of *klhl24a* in cardiac development.

To address the role of *klhl24a*, we used an antisense morpholino oligonucleotide (MO) technique to knockdown the protein. The general development of morpholino-injected embryos was normal, however, defects in heart function started to become detectable after 48 hpf. Heart defects initially manifested as pericardial edema, changed heart rate and reduced blood circulation (Fig. 6J, Supplementary Video 1 and 2), later resulted in ventricular failure and blocked blood circulation in 90% of the *klhl24a* morphants (n = 179, Fig. 6G-I) as compared to 4% in embryos injected with control morpholino (n = 119. Fig. 6E,F,I). Injection of a second morpholino (sMO2), targeting the boundary between exon- and intron 4, resulted in similar phenotypes as with sMO1 (Fig. 6I). Changes in *klhl24a* mRNA splicing was confirmed with RT-PCR using primers specific for surrounding exons (Fig. 7A). The identity of the atrium and ventricle is maintained in *klhl24a* sMO1 injected embryos as shown by the cardiac myosin light chain 2 gene (*cmlc2*) expression at 48 hpf but the morphology of the ventricle is changed as compared with control MO injected embryos (Fig. 7B).

Immunoblotting using an antibody against desmin (D8281 Sigma 1:100) could not detect any obvious change in the protein expression of desmin in *klh24a* sMO1 embryos at 52 hpf relative to control MO-injected embryos. The short time span of the fish experiments and differences in cell metabolism between fish and human may explain this difference.
To confirm the specificity of the morpholino, we addressed if full-length *klhl24a* mRNA could rescue the heart defect. Co-injections of mRNA and sMO1 resulted in an increased number of embryos with normal heart formation (51.5%, n = 178) as compared to embryos injected with *klhl24a* sMO1 alone (16%, n = 108). We then addressed the effect of the human KLHL24 variants on protein function in zebrafish and made site-specific mutagenesis at the corresponding conserved amino acids in the zebrafish *klhl24a* gene. The lack of one amino acid in the N-terminal of zebrafish Klhl24a compared to human KLHL24 (Supplementary Fig. 6) make the homologous mutation shifted three nucleotides and was thus made at 914G>A (R305H) and at 1045G>T (E349*). Co-injection of sMO1 and *klhl24a* 914 mRNA (n= 123) or *klhl24a* 1045 mRNA (n=107) gave rise to heart defects in 71.5% and 77.5% of all embryos respectively and were thus not able to rescue the knockdown of the endogenous *klhl24a* (Fig. 6K).

Together, these results show that *klhl24a* has a role during heart development, especially in the formation of a functional ventricle, and support that both mutations found in human KLHL24 with HCM are loss-of-function mutations.

**Discussion**

We describe a new cardiomyopathy that mimics HCM and is associated with biallelic mutations in *KLHL24*. By morphological studies on heart and skeletal muscle, molecular genetic investigations and experimental studies on zebrafish, we provide evidence that the disease is caused by inactivation of Kelch-like protein 24. In the Genotype-Tissue Expression (GTEx) Portal Database, *KLHL24*, which encodes a member of the KLHL (Kelch-like) protein family, shows the highest expression in skeletal
muscle, followed by lung and the heart, supporting a role for this protein in muscle (3). The
importance of KLHL24 is further supported by a high degree of conservation throughout the
protein in vertebrates. The KLHL24 gene has a Residual Variation Intolerance Score (RVIS)
of -0.78 and a percentile of 13.22 % meaning it is among 13.22 % of human genes most
intolerant to functional genetic variants. Furthermore, missense and loss of function variants
in this gene are extremely rare. By exome sequencing, supported by genome-wide linkage
analysis, we identified homozygous and most likely pathogenic variants in KLHL24 in
affected individuals of both families.

To gain additional support for a causal association between the KLHL24 variants and cardiac
function, we investigated the tissue specific expression and effect of downregulation of
klhl24a in the zebrafish. The strong klhl24a expression in early ventricular myocytes and later
in the established heart ventricle suggest a pivotal role for Klhl24a during cardiogenesis.
Further, the lack of function of zebrafish klhl24a mRNA carrying the human mutations (917
or 1048) strongly suggests that both mutations result in a loss-of-function protein. In humans,
the pathogenesis of HCM include various mechanisms including structural abnormalities and
deficiencies in the contractile machinery. Zebrafish has gained increasing attention as a
vertebrate model system for investigating the molecular basis of heart development and
disease. However, heart disease in the zebrafish frequently appears different from that in
humans in spite of the same genetic or cellular deficit. Previous reported studies on mutations
in orthologues to TNNCI (6), MYBPC (7) MYH7 (8) and TNNT2 (9), all known to cause
HCM in humans, demonstrated decreased ventricle size and heart failure in zebrafish similar
to that reported by us in this study. We therefore conclude that our result strengthen a role for
KLHL24 in HCM since knockdown of Klhl24a display phenotypes similar to those observed
with loss of function studies of other HCM genes in zebrafish.
The KLHL proteins are involved in a variety of cellular processes such as cytoskeletal organization, regulation of cell morphology, cell migration, protein degradation, and gene expression (10-13). Many Kelch-like proteins have been identified as adaptors for the recruitment of substrates to Cul3-based E3 ubiquitin ligases (14-16). Furthermore there are many examples of kelch-like proteins associated with disorders of the sarcomere (17). The involvement of Kelch-like proteins in muscle structural protein turnover thus appears to be important and a research field to be further explored.

Since KLHL24 is highly expressed in striated muscle cells, it may be important for the processing of intermediate filaments specific for muscle, such as desmin. The accumulation of desmin observed in both heart and skeletal muscle may be an effect of insufficient degradation due to a lack of functional KLHL24. It is well established that desmin is important for both structure and function of muscle cells and dominant mutations in desmin cause a severe form of cardiomyopathy with desmin accumulation (18-21). Therefore the identified up regulation of desmin in our patients may be part of the pathogenesis. The unique pathological alterations with accumulation of desmin, glycogen and tubular structures in skeletal muscle that were present in individuals from both families, further supports a shared disease aetiology. Whilst no skin abnormalities were noted in our families, two patients with epidermolysis bullosa caused by a dominant initiation codon mutation in KLHL24, were also described to develop a dilated cardiomyopathy, a finding that further supports the concept that mutations in KLHL24 are associated with cardiomyopathy (4, 22, 23).

We identified accumulation of polyglucosan in the heart. Cardiomyopathies with polyglucosan accumulation are restricted to a few diseases, which are generally disorders of glycogen metabolism (24). However, no pathogenic variants were identified in genes known
to be associated with polyglucosan storage diseases. The pathogenesis of the polyglucosan
storage in our patients remains unknown, but may serve as a diagnostic marker.

In conclusion we describe a new cardiomyopathy that mimics HCM and is associated with
mutations in *KLHL24*. It is histologically characterized by polyglucosan accumulation in
some cardiomyocytes and with accumulation of glycogen, desmin, and tubular structures in
the cardiomyocytes and in skeletal muscle fibres. The skeletal muscle biopsies showed unique
pathological alterations not previously described. Since the jagged structure of the periphery
of the muscle fibers gave them a cogwheel appearance we suggest that this pathological
change is referred to as “cogwheel” fibers that may be used as a diagnostic marker. Several
individuals suffered fatal sudden cardiac arrest. Experience from additional cases may clarify
if arrhythmias are a common complication in *KLHL24* associated cardiomyopathy and
increase the need for early diagnosis.

**Material and Methods**

**Morphological investigations of myocardium and skeletal muscle**

Endomyocardial biopsy was performed in individual III:1 and III:2 in Family A. The
specimens were fixed in paraformaldehyde for paraffin embedding or glutaraldehyde for
electron microscopy. In individual III:2 an additional myocardial specimen was fresh frozen.
After cardiac transplantation in individual III:2 the cardiac explant was fixed in
paraformaldehyde and specimens were embedded in paraffin for histological examination.
Routine staining methods were applied including hematoxylin-eosin, van-Gieson, and
Periodic acid and Schiff (PAS) staining for glycogen before and after digestion with alpha-
amylase. Specimens fixed in glutaraldehyde were postfixed in osmium-tetroxide and
embedded in resin. Ultrathin sections were contrasted with uranyl acetate and lead citrate and
examined by electron microscopy.
Skeletal muscle biopsy was performed in individual III:1 and III:2 in Family A and V:5 in family B. Specimens were snap frozen and sections for histochemical investigations were prepared in a cryostat. A battery of histochemical staining’s were applied and included hematoxylin-eosin (general morphology), Gömöri trichrome (general morphology), myofibrillar ATPase (different muscle fiber types), NADH-tetrazolium reductase (sarcoplasmic reticulum and mitochondria), succinate dehydrogenase (mitochondria), cytochrome c oxidase (mitochondria), PAS (glycogen) and oilred O (fat) (25). Immunohistochemical staining included sarcolemmal proteins such as dystrophin, different sarcoglycans, alpha-dystroglycan and spectrin. Immunohistochemical staining of desmin as a muscle specific intermediate filament was performed and lysosomal associated membrane protein-2 (Lamp2) was included as a marker for lysosomes (25).

Molecular genetic analysis

We performed exome sequencing (ES) on genomic DNA from individuals III:1 and III:2 in family A and individuals V:2 and V:4 in family B. Filtering was performed for high quality variants that were classified as deleterious (missense, nonsense, indel and splice-site variants +/- 5bp around exon boundaries) and rare (<0.5% minor allele frequency in the ExAC Browser, gnomAD or 1000 Genomes). Assuming a recessive mode of inheritance for the clinical phenotype in the studied families and considering the consanguineous marriage, we compared the exomes of the two affected siblings in each family in a search for homozygous variants in genes associated with inherited cardiac conditions (gene panel of 88 genes) or polyglucosan storage disease (9 genes) (Supplementary methods). After excluding these candidate genes, rare variants shared between the two affected sibs in each family were selected and with the assumption of recessive inheritance. Variants of interest were further evaluated by the following prediction tools: PhyloP, SIFT, PolyPhen-2, and MutationTaster (Supplementary Table 1-2).
In family B, homozygosity mapping was performed under the assumption that the causative variant would be homozygous and identical by descent in the affected children. Genomic DNA samples from the five affected individuals (V:2, V:4, V:5, V:7, V:9) were subjected to genotyping using the Infinium Global Screening Array-24 v1.0 BeadChip (Illumina, San Diego, CA, USA). This array contains 642,824 markers selected from over 26 global populations and has a mean marker density of one marker per ~4.5 kb. Arrays were performed in accordance with manufacturer’s protocols. Genotyping data were analysed using Homozygosity Mapper to identify common homozygous intervals among the affected individuals (PMID: 19465395). Runs of homozygosity with a maximum threshold of 0.99 were included in the analysis. These regions were further cross-referenced to support results.

**Protein expression by immunoblotting**

Western blot analyses were performed on protein extract from fresh frozen skeletal muscle and cardiac muscle biopsy specimens from patient III:1 and III:2 from family A. The protein extractions were performed by denaturing the samples using Laemmli sample buffer with 5% β-mercaptoethanol, incubating 4 min at 95°C and a final centrifugation for 10 min. The supernatants including protein were loaded and separated on 4-12% Bis-Tris gel (Novex; Life Technologies, Grand Island, NY) followed by electroblotting. The membranes were incubated with primary antihuman-desmin antibody (Dako, M0760; clone D33); 1:250. Western Breeze Chromogenic kit (Life Technologies) was used for antibody detection.

**Cloning and mutagenesis of zebrafish klhl24a**

The spatiotemporal expression of klhl24a and klhl24b was analysed with whole-mount in situ hybridization using transcribed antisense mRNA probes on embryos treated with 0.003% 1-phenyl 2-thiourea. Full-length klhl24a and klhl24b were amplified from total RNA at 2 days
post fertilization (dpf) using gene-specific primers, cloned into the pCS2+ vector and sequenced to confirm maintained reading frame. Site specific mutagenesis of zebrafish klhl24a was performed, following the instructions in the QuikChange II site-directed mutagenesis protocol (Agilent Technologies, Santa Clara, CA) (Supplementary Table 5).

**Functional analysis of KLHL24 in zebrafish**

Zebrafish of AB background were maintained in a 14h:10h light:dark cycle at 28.5°C, at the facility of the Institute of Neuroscience and Physiology, University of Gothenburg. To determine the function of klhl24a in heart development, we used an antisense morpholino oligonucleotide (MO) technique to knock-down the protein (klhl24a sMO1, 3 ng and klhl24a sMO2, 6 ng) and a standard control MO at an equal amount. Morpholino-modified splice-targeting anti-sense oligonucleotides (MOs) were injected at the one- to two-cell stage and the specificity of the MOs analysed with RT-PCR on total RNA extracted from 2dpf with TRI Reagent (Sigma, 93 289) according to manufacturer’s protocol (26). Injection of a second morpholino (sMO2), targeting the splice site of exon 4 was also performed, as assessed by RT-PCR using primers specific for surrounding exons (Supplementary Table 5) (Fig. 7).

Rescue experiments used in vitro transcribed full-length mRNA from klhl24a-pCS2+ plasmid with mMessenage mMachine SP6 kit (ThermoFisher, AM1340). Co-injections were performed at one- to two cell stage with 2ng sMO1 and 12.5pg klhl24a mRNA or containing the 914 or 1045 mutations.

**Study approval and consent to participate.** The present study was approved by the Regional ethical review board in Gothenburg, Sweden. The study complies with the Declaration of Helsinki and informed consent has been obtained from the patients.

**Supplementary Material**
Acknowledgments

We are grateful to the patients and their families who contributed to this study. We’d also like to thank Prof Thomas Haaf for his support of the mapping work that was carried out.

Conflict of Interest statement. None declared.

Funding

The study was supported by the Research Fund for Neuromuscular Disorders in West Sweden, Knut and Alice Wallenberg Foundation, the Swedish Research Council grant numbers 2012-2014 (AO) and 2013-2546 (HZ), and the Swedish Heart-Lung Foundation grant number 20180236 (AO).

Additional information

Supplementary Information online
References


Figures and Figures legends

**Fig. 1.** Pedigrees for two consanguineous families. Filled squares and circles indicate individuals with cardiomyopathy. Asterisks indicate the individuals whose DNA was analysed by whole-exome sequencing. Individual III:4 in family A died suddenly at the age of 20. In family B individual V:3 died suddenly at 26 years of age and V:10 died of sudden cardiac arrest at the age of 26. +/- heterozygous and -/- homozygous for the **KLHL24** variant.

**Fig. 2.** Histopathology of the heart in family A. (A‒G) Cardiac explant from individual III:2 after fixation in paraformaldehyde and paraffin embedding. (A and B). There is accumulation of glycogen as revealed by PAS staining (A). Cardiomyocytes have often accumulated PAS-positive material that is alpha-amylase resistant (polyglucosan; arrows) (PAS-D: PAS-diastase). (C) Accumulation of polyglucosan in cardiomyocytes (PAS-Diastase). (D and E) Scattered cardiomyocytes, many of which include polyglucosan (arrows), are associated with inflammatory cells. (F) The inflammatory cells stain positively for CD68, a marker for macrophages. (G) There is patchy fibrosis in the heart that stains red on van Gieson staining, compared to brownish cardiomyocytes. (H and I) Electron microscopy of endomyocardial biopsy material from individual III:1 after glutaraldehyde fixation and embedding in resin. Polyglucosan (arrow in panel H) is associated with intermyofibrillar accumulation of glycogen, filaments, and tubular structures, which are seen at higher magnification in panel I.

**Fig. 3.** Skeletal muscle biopsy from three individuals from two families with cardiomyopathy and homozygous **KLHL24** variants, and a normal control. (A‒H) In all three individuals with cardiomyopathy a characteristic cogwheel appearance of the fibers are present due to jagged accumulation of glycogen (PAS staining) and intermediate filaments (desmin immunostaining). Electron microscopy (I, J) of individual III:2 shows focal subsarcolemmal accumulation of glycogen, tubular structures and intermediate filaments (arrows).
**Fig. 4.** Molecular genetics analysis. (A) Illustration showing the different domains in the KLHL24 protein; variants are indicated by red bars. (B) Chromatogram demonstrating the homozygous variant c.1048G>T (p.Glu350*) in family A. (C) Chromatogram demonstrating the homozygous variant c.917G>A (p.Arg306His) in family B. (D) Illustration showing the evolutionary conservation of the amino acids. The mutated residue (p.Arg306His) is indicated by the red bar. (E) Homozygosity mapping results from Family B showing homozygous regions in a view of chromosome 3 which reveals the longest run of homozygosity containing the candidate variant and spans the coordinates chr3:182,207,825-185,614,988 (rs9877496 to rs73175592) which is approximately 3.4 Mb in length. (F) Gene expression for KLHL24 in the Genotype-Tissue Expression (GTEx) Portal Database with the highest expression in skeletal muscle, followed by lung and the left ventricle of the heart, Data Source: GTEx Analysis Release V6p (dbGaP Accession phs000424.v6.p1).

**Fig. 5.** Western blot analysis of desmin in protein extracted from skeletal muscle biopsies and heart muscle specimens showed up regulation of desmin compared to control sample both in the skeletal muscle and the heart muscle. The band corresponding to myosin heavy chain was used as loading control. Each lane represents one unique specimen. Control 3 is a normal heart whereas control 4 is a heart explant of a patient with cardiomyopathy with an expected moderate up regulation of desmin(27).

**Fig. 6. Expression and functional analysis of klhl24 in zebrafish.**

(A–D) Whole-mount in situ hybridization of klhl24a and klhl24b at 22 hpf (A-B; dorsal view, head left) and 72 hpf (C-D; front view, dorsal up). Expression of klhl24a mRNA in the cardiac cone at 22 hpf (A, dotted circle) and heart (C, dotted line) at 72 hpf. (E-H) Morphology of embryos injected with control anti-sense morpholino (E-F) or klhl24a sMO1
(G-H) at 72 hpf with close-up on the heart region (F, H). Scale bar, 100 μM. V; ventricle, A;
atrium. (I) Phenotypic distribution of embryos injected with control or klhl24a morpholinos.
Embryos were categorized as normal (normal appearance), heart defect (otherwise normal),
moderate (non-cardiac related abnormalities) or severe/dead (severely altered morphology or
dead). (J) Contractions of atrium or ventricle as beats per minute analysed with the non-
parametric Mann-Whitney t-test, with SEM. ***P < 0.001. (K) Phenotypic distribution in
percentage of un-injected embryos or injected with sMO1, sMO1+12.5 pg klhl24a mRNA,
sMO1+12.5 pg klhl24a 914 mRNA or sMO1+12.5 pg klhl24a1045.

Fig. 7. RT-PCR analysis of splicing of klhl24a mRNA using primers (arrows) located in
exon 2 and 6 surrounding the binding site of the sMO1 (asterisk). Control and klhl24a
sMO1 injected embryos were analysed. No reverse transcriptase (RT) served as negative
control (-RT). One PCR fragment of sMO1 injected embryos is shorter than that of control
injected embryos. Sanger sequencing of the PCR product showed that exon 3 is skipped in
sMO1 injected embryos resulting in a premature stop in exon 4. (B) Expression of cmlec2 in
heart of control and klhl24a sMO1 morpholino injected embryos at 48 hpf. Scale bar, 100
μM.
<table>
<thead>
<tr>
<th>Family</th>
<th>Age, years</th>
<th>Age of onset, (years)</th>
<th>Initial symptoms</th>
<th>ICD (years)</th>
<th>ECG</th>
<th>Echocardiogram (age, years)</th>
<th>Echocardiogram results</th>
<th>Left ventricular (LV) end-diastolic volume, (mL)</th>
<th>Septal wall thickness, (cm)</th>
<th>Posterior wall thickness (cm)</th>
<th>Ejection fraction, (%)</th>
<th>Coronary angiogram</th>
<th>Heart transplant, (age, years)</th>
<th>Dermatological findings</th>
<th>KLIHL24 mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>32</td>
<td>28</td>
<td>Palpitations, vertigo and shortness of breath</td>
<td>Sinus rhythm. General ST-T changes, PR 194 ms, QRS duration 120 ms, Frequent episodes of non-sustained VT</td>
<td>Normal sinus rhythm</td>
<td>28</td>
<td>Left ventricular outflow tract obstruction. Left atrium slightly dilated. No valve abnormalities</td>
<td>Moderately dilated left ventricle with regions of akinesia. Left atrium slightly dilated. No valve abnormalities</td>
<td>83</td>
<td>2.0</td>
<td>2.8</td>
<td>50</td>
<td>Normal</td>
<td>-</td>
<td>Dark-haired, without freckles, no skin problems</td>
</tr>
<tr>
<td>III:1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Small left ventricular cavity, severe concentric left ventricular hypertrophy, no SAM, mild mitral regurgitation</td>
<td>ASH</td>
<td>37</td>
<td>2.2</td>
<td>1.9</td>
<td>67</td>
<td>Normal</td>
<td>26</td>
</tr>
<tr>
<td>III:2</td>
<td>27</td>
<td>19</td>
<td>Palpitations, dyspnea on exertion</td>
<td>Sinus rhythm. General ST-T changes; PR 210 ms</td>
<td>ST-T change; PR 210 ms</td>
<td>23</td>
<td>Moderately dilated left ventricle with regions of akinesia. Left atrium slightly dilated. No valve abnormalities</td>
<td>ASH, left ventricular outflow tract obstruction = 48 mmHg, moderate SAM</td>
<td>146</td>
<td>0.9</td>
<td>1.5</td>
<td>25</td>
<td>Normal</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>V:2</td>
<td>36</td>
<td>35</td>
<td>Palpitations, dyspnea on exertion</td>
<td>Sinus rhythm. General ST-T changes, PR 188 ms, QRS duration 120 ms, Frequent episodes of non-sustained VT</td>
<td>Normal sinus rhythm</td>
<td>32</td>
<td>Small left ventricular cavity, severe concentric left ventricular hypertrophy, no SAM, mild mitral regurgitation</td>
<td>ASH</td>
<td>40</td>
<td>2.2</td>
<td>0.8</td>
<td>65</td>
<td>nd</td>
<td>nd</td>
<td>-</td>
</tr>
<tr>
<td>V:3</td>
<td>27</td>
<td>-</td>
<td>Systolic anterior motion of the mitral valve</td>
<td>General ST-T changes; PR 186 ms, QRS duration 125 ms</td>
<td>General ST-T changes, PR 210 ms</td>
<td>-</td>
<td>Small left ventricular cavity, severe concentric left ventricular hypertrophy, no SAM, mild mitral regurgitation</td>
<td>-</td>
<td>37</td>
<td>2.2</td>
<td>1</td>
<td>-</td>
<td>nd</td>
<td>nd</td>
<td>-</td>
</tr>
<tr>
<td>V:4</td>
<td>17</td>
<td>nd</td>
<td>Palpitations, dyspnea on exertion</td>
<td>Sinus rhythm. General ST-T changes, PR 188 ms, QRS duration 120 ms, Frequent episodes of non-sustained VT</td>
<td>Normal sinus rhythm</td>
<td>-</td>
<td>Small left ventricular cavity, severe concentric left ventricular hypertrophy, no SAM, mild mitral regurgitation</td>
<td>-</td>
<td>37</td>
<td>1.4</td>
<td>0.8</td>
<td>-</td>
<td>nd</td>
<td>nd</td>
<td>-</td>
</tr>
<tr>
<td>V:5</td>
<td>32</td>
<td>nd</td>
<td>Dyspnea on exertion</td>
<td>Sinus rhythm. General ST-T changes; PR 186 ms, QRS duration 125 ms</td>
<td>General ST-T changes, PR 210 ms</td>
<td>-</td>
<td>Small left ventricular cavity, severe concentric left ventricular hypertrophy, no SAM, mild mitral regurgitation</td>
<td>-</td>
<td>47</td>
<td>1.3</td>
<td>1.3</td>
<td>-</td>
<td>nd</td>
<td>nd</td>
<td>-</td>
</tr>
<tr>
<td>V:7</td>
<td>29</td>
<td>31</td>
<td>Dyspnea on exertion</td>
<td>Sinus rhythm. General ST-T changes; PR 186 ms, QRS duration 125 ms</td>
<td>General ST-T changes, PR 210 ms</td>
<td>nd</td>
<td>Small left ventricular cavity, severe concentric left ventricular hypertrophy, no SAM, mild mitral regurgitation</td>
<td>-</td>
<td>nd</td>
<td>35</td>
<td>35</td>
<td>-</td>
<td>nd</td>
<td>nd</td>
<td>-</td>
</tr>
<tr>
<td>V:9</td>
<td>28</td>
<td>28</td>
<td>Dyspnea on exertion</td>
<td>General ST-T changes, PR 186 ms, QRS duration 125 ms</td>
<td>General ST-T changes, PR 210 ms</td>
<td>24</td>
<td>Small left ventricular cavity, severe concentric left ventricular hypertrophy, no SAM, mild mitral regurgitation</td>
<td>-</td>
<td>nd</td>
<td>40-45</td>
<td>40-45</td>
<td>-</td>
<td>nd</td>
<td>nd</td>
<td>-</td>
</tr>
</tbody>
</table>

- **ICD**: implantable cardioverter defibrillator; **SAM**: systolic anterior motion of the mitral valve

- **KLHL24 mutation**
  - c.1048G>T p.E350* homozygous
  - c.917G>A p.R306H homozygous

- **KLIHL24 mutation**
  - c.1048G>T p.E350* homozygous
  - c.917G>A p.R306H homozygous
  - nd

- **KLHL24 mutation**
  - c.917G>A p.R306H homozygous
  - nd

- **KLHL24 mutation**
  - c.917G>A p.R306H homozygous
  - nd

- **KLHL24 mutation**
  - c.917G>A p.R306H homozygous
  - nd

- **KLHL24 mutation**
  - c.917G>A p.R306H homozygous
  - nd